We are pleased to have secured financing - giving us runway into 2025 -- through two financing events in 2022. In July, we raised USD 70m through a non-dilutive financing transaction with NovaQuest and in December, raised USD 40m in a directed share issue targeting U.S. and other international healthcare specialist investors. Together these transactions will help finance preparations for a potential U.S. launch of imlifidase in kidney transplantation, strengthen ongoing product development activities and expand the Company's R&D pipeline.
We anticipate an exciting year ahead, with several key milestones across our platform and therapy areas, as we continue the development of new, transformative medicines for patients suffering from serious, rare immunologic diseases."
Upcoming milestones and news flow
H1 2023 GBS Phase 2: Complete enrollment
H1 2023 Anti-GBM Phase 3: First patient enrolled
H1 2023 U.S. Kidney transplantation (ConfIdeS): Complete enrollment
H1 2023 HNSA 5487 (Lead NiceR candidate): Initiate Phase 1 study
2023 Sarepta DMD pre-treatment: Commence clinical study
H2 2023 Long-term follow-up study in kidney transplantation: 5-year data readout
H2 2023 AMR Phase 2: Full data readout
H2 2023 GBS Phase 2: First data readout
H2 2023 U.S. Kidney transplantation (ConfIdeS): Complete randomization
2024 U.S. Kidney transplantation (ConfIdeS): BLA submission
Updated financial calendar 2023
March 30, 2023 2022 Annual Report
April 20, 2023 Interim Report for January-March 2023
June 14, 2023 2023 Annual General Meeting
July 20, 2023 Half-year Report for January-June 2023
October 18, 2023 Interim Report for January-September 2023
Conference call details
Hansa Biopharma will host a telephone conference today Thursday February 2 2023, 14:00 CET / 8:00am EST.
The presentation will be held in English and be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota. Slides used in the presentation will be live on the company website during the call under "Events & Presentation" and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details provided below:
Sweden: +46 10 884 80 16
United Kingdom: +44 020 3936 2999
United States: +1 646 664 1960
Participant access code: 031372
The webcast will be available on https://events.q4inc.com/attendee/195504216
The Year-end report and latest investor presentation can be downloaded from our web
Year-end report January to December 2022 https://www.hansabiopharma.com/investors/financial-reports/
Investor road show presentation Q4, 2022 https://www.hansabiopharma.com/investors/presentations/
This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.
For further information, please contact:
Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709--298 269
E: klaus.sindahl@hansabiopharma.com
Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com
The following files are available for download:
https://mb.cision.com/Main/1219/370741 20230202 HNSA - Q4 2022 Quarterly 3/1821262.pdf Report ENG BoD FINAL
View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-year-end-report-january-december-2022-301737108.html
SOURCE Hansa Biopharma AB
(END) Dow Jones Newswires
February 02, 2023 02:38 ET (07:38 GMT)
Comments